Sodium-glucose transport: Role in diabetes mellitus and potential clinical implications

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 5, 2010, Pages 425-431

  Vallon, Volker ^a,b   Sharma, Kumar ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

albuminuria; diabetic kidney disease; glucose transport; glycemic control

Indexed keywords

ANTIDIABETIC AGENT; DAPAGLIFLOZIN; ISIS 388626; PHLORIZIN; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

DIABETIC NEPHROPATHY; DRUG HALF LIFE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE ABSORPTION; GLUCOSE TRANSPORT; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; KIDNEY PROXIMAL TUBULE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; WEIGHT REDUCTION;

ABSORPTION; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLUCOSE; GLUCOSIDES; HUMANS; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 77955919466     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32833bec06     Document Type: Review

References (65)

1. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch 2004; 447:510-518.
2. You G, Lee WS, Barros EJ, et al. Molecular characteristics of Na(\+)-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 1995; 270:29365-29371.
3. Wright EM. Renal Na(\+)-glucose cotransporters. Am J Physiol Renal Physiol 2001; 280:F10-F18.
4. Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na\+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93:397-404.
5. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003; 89:3-9.
6. Chin E, Zhou J, Bondy C. Anatomical and developmental patterns of facil-itative glucose transporter gene expression in the rat kidney. J Clin Invest 1993; 91:1810-1815.
7. Wright EM, Martin MG, Turk E. Familial glucose-galactose malabsorption and hereditary renal glycosuria. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. Metabolic basis of inherited disease, 8th ed. New York: McGraw-Hill; 2001. pp. 4891-4980.
8. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010; 5:133-141.
9. Van Den Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 2002; 111:544-547.
10. Francis J, Zhang J, Farhi A, et al. A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrol Dial Transplant 2004; 19:2893-2895.
11. Magen D, Sprecher E, Zelikovic I, Skorecki K. A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int 2005; 67:34-41.
12. Scholl-Burgi S, Santer R, Ehrich JH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant 2004; 19:2394-2396.
13. Vallon V, Platt KA, Cunard R, et al. Lack of early proximal tubular glucose reabsorption in transgenic Sglt2 null mice. J Am Soc Nephrol 2010; in press.
14. Albertoni Borghese MF, Majowicz MP, Ortiz MC, et al. Expression and activity of SGLT2 in diabetes induced by streptozotocin: relationship with the lipid environment. Nephron Physiol 2009; 112:45-52.
15. Adachi T, Yasuda K, Okamoto Y, et al. T-1095, a renal Na\+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism 2000; 49:990-995.
16. Vestri S, Okamoto MM, De Freitas HS, et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 2001; 182:105-112.
17. Han HJ, Lee YJ, Park SH, et al. High glucose-induced oxidative stress inhibits Na\+/glucose cotransporter activity in renal proximal tubule cells. Am J Physiol Renal Physiol 2005; 288:F988-F996.
18. Osorio H, Bautista R, Rios A, et al. Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats. Diabetes Res Clin Pract 2009; 86:e46-e49.
19. Rahmoune H, Thompson PW, Ward JM, etal. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with noninsulin-dependent diabetes. Diabetes 2005; 54:3427-3434.
20. Freitas HS, Anhe GF, Melo KF, et al. Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 2008; 149:717-724.
21. Freitas HS, Schaan BD, David-Silva A, et al. SLC2A2 gene expression in kidney of diabetic rats is regulated by HNF-1alpha and HNF-3beta. Mol Cell Endocrinol 2009; 305:63-70.
22. Prasad P, Tiwari AK, Kumar KM, et al. Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms. BMC Med Genet 2006; 7:42.
23. Vieitez P, Gomez O, UcedaER, et al. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy. J Renin Angiotensin Aldosterone Syst 2008; 9:96-102.
24. Tiwari AK, Prasad P, BKT, et al. Oxidative stress pathway genes and chronic renal insufficiency in Asian Indians with type 2 diabetes. J Diabetes Complications 2009, 23:102-111.
25. Prasad P, Tiwari AK, Kumar KM, et al. Association analysis of ADPRT1, AKR1B1, RAGE, GFPT2 and PAI-1 gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes. BMC Med Genet 2010; 11:52.
26. Zhu Y, Usui HK, Sharma K. Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. Semin Nephrol 2007; 27:153-160.
27. Prasad P, Tiwari AK, Kumar KM, et al. Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. BMC Med Genet 2007; 8:20.
28. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 311:89-93.
29. Mogensen CE. Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy. Scand J Clin Lab Invest 1986; 46:201-206.
30. Vallon V, Richter K, Blantz RC, et al. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 1999; 10:2569-2576.
31. Vallon V, Blantz RC, Thomson S. Glomerular hyperfiltration and the salt paradox in early type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol 2003; 14:530-537.
32. Thomson SC, Deng A, Bao D, et al. Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest 2001; 107:217-224.
33. Vallon V, Schroth J, Satriano J, et al. Adenosine A(1) receptors determine glomerular hyperfiltration and the salt paradox in early streptozotocin diabetes mellitus. Nephron Physiol 2009; 111:30-38.
34. Sharma K, Cook A, Smith M, et al. TGF-beta impairs renal autoregulation via generation of ROS. Am J Physiol Renal Physiol 2005; 288:F1069-F1077.
35. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003; 284:F1138-F1144.
36. Lemley KV. Diabetes and chronic kidney disease: lessons from the Pima Indians. Pediatr Nephrol 2008; 23:1933-1940.
37. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. J Am Med Assoc 2002; 287:360-372.
38. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 1999; 281:2005-2012.
39. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
40. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005; 21:31-38.
41. Ueta K, Ishihara T, Matsumoto Y, et al. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci 2005; 76:2655-2668.
42. Arakawa K, Ishihara T, Oku A, et al. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 2001; 132:578-586.
43. Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999; 48:1794-1800.
44. Wancewicz E, Bernd A, Meibohm B, et al. Long-term safety and efficacy of ISIS-388626, an optimized SGLT2 antisense inhibitor, in multiple diabetic and euglycemic species. Diabetes 2008; 57 (Suppl):A96. (Abstract).
45. Bhanot S, Murray S, Booten S, etal. ISIS 388626, an SGLT2 antisense drug, causes robust and sustained glucosuria in multiple species and is safe and well tolerated. Proc of the 69th Scientific Session of the American Diabetes Association 2009, New Orleans, LA (Abstract 328-OR).
46. Meng W, Ellsworth BA, Nirschl AA, etal. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51:1145-1149.
47. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57:1723-1729.
48. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85:520-526.
49. Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharma cokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotran sporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010; 38:405-414.
50. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32:650-657.
51. Wilding JP, Norwood P,T'joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32:1656-1662.
52. Katsuno K, Fujimori Y, TakemuraY, etal. Sergliflozin,a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007; 320:323-330.
53. Fujimori Y, Katsuno K, Ojima K, et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009; 609:148-154.
54. Katsuno K, Fujimori Y, Ishikawa-TakemuraY, Isaji M. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol 2009; 618:98-104.
55. Hussey EK, Clark RV, Amin DM, et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 2010 [Epub ahead of print].
56. Hussey EK, Dobbins RL, Stoltz RR, etal. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol 2010 [Epub ahead of print].
57. Fujimori Y, Katsuno K, Nakashima I, et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327:268-276.
58. Hussey EK, O'Connor-Semmes RL, Tao W, et al. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate (SGLT2 inhibitor) and metformin when co-administered in type 2 diabetes mellitus patients. Proc of the 69th Scientific Session of the American Diabetes Association 2009, New Orleans (Abstract 509-P).
59. Kapur A, Hussey EK, Dobbins RL, et al. First human dose escalation study with remogliflozin etabonate (RE) in healthy subjects and in subjects with type 2 diabetes mellitus. Proc of the 69th Scientific Session of the American Diabetes Association 2009, New Orleans (Abstract 509-P).
60. Bickel M, Brummerhop H, Frick W, et al. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung 2008; 58:574-580.
61. Grempler R, Thomas L, Eckhardt M, et al. In vitro properties and in vivo effect on urinary glucose excretion of BI 10773, a novel selective SGLT2 inhibitor. Proc of the 69th Scientific Session of the American Diabetes Association 2009, New Orleans (Abstract 521-P).
62. US National Institutes of Health.ClinicalTrials.gov [online]. Available from URL. http://www.clinicaltrials.gov 2010.
63. Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, et al. (1S)-1,5-anhydro-1-[5-(4- ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 2010; 53:3247-3261.
64. O'Malley D, Reimann F, Simpson AK, Gribble FM. Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing. Diabetes 2006; 55:3381-3386.
65. Zhou L, Cryan EV, D'Andrea MR, et al. Human cardiomyocytes express high level of Na\+/glucose cotransporter 1 (SGLT1). J Cell Biochem 2003; 90:339-346.